legend

Innovation is the Key Benchmark, Focus on Four Healthcare Industry Sub-Sectors in 2023, Says Jafar Wang of Legend Capital

indie 15 2 月

8 minutes

HONG KONG, Feb 15, 2023 - (ACN Newswire via SEAPRWire.com) - Legend Capital invested in 29 healthcare companies that officially disclosed financing rounds in 2022, according to the VBDATA Database. Since 2007, Legend Capital has continuously invested in healthcare across industry sub-sectors including innovative drugs, biotechnology, medical devices, diagnostic technology, professional services and supply chain. Overtime, it has built a powerful healthcare ecosystem encompassing more than 140 portfolio companies. Through value-added initiatives including strategic management and business empowerment activities, Legend Capital has the capability to bring far more value to the table in addition to financial resources.Breakthrough and global innovations are the key benchmarks by which Legend Capital judges and selects projects in a changing external environment. How did Legend Capital navigate the challenges of 2022 and how does it see the market in 2023? What are the key healthcare investment themes? In an interview with VCBeat, Jafar Wang, Co-Chief Investment Officer of Legend Capital, shared his perspectives:"Five significant changes in primary market investments"Legend Capital obs...

Legend Capital Portfolio Company Bespin Global Completes USD100m Series D Financing

indie 15 12 月

3 minutes

HONG KONG, Dec 15, 2022 - (ACN Newswire via SEAPRWire.com) - Legend Capital Portfolio Company Bespin Global, a Korea-headquartered cloud services company, has recently completed its Series D round financing of USD100 million, which will be used mostly for acquisitions.Concurrent with the investment, the investor, e& Enterprise, a leading digital services provider in UAE (formerly Etisalat Digital), and Bespin Global will form a joint venture that will serve customers in the Middle East, North Africa and Pakistan.John HanJoo Lee, CEO and co-founder of Bespin Global said, "By combining forces with e& enterprise in the METAP region, we are bringing much needed cloud managed services to the region where cloud adoption is about to explode. e& enterprise has deep customer relationships and the trust of its customers and Bespin Global has the deep cloud management capabilities. Together, we can accelerate cloud adoption in the region. Additionally, we welcome e& as our shareholder. It's a clear validation of our track record as a trusted cloud managed services provider on the global stage."Bespin Global helps its customers in their digital transformation by providing cloud...

Led by Legend Capital, GS Biotech Completes Nearly CNY100 million Pre-A Round Financing

indie 9 12 月

5 minutes

HONG KONG, Dec 9, 2022 - (ACN Newswire via SEAPRWire.com) - Recently, Zhongke Guosheng (Hangzhou) Technology Co., Ltd (hereinafter referred to as "GS Biotech") officially announced the completion of its nearly CNY100 million pre-A round financing, led by Legend Capital. The proceeds will be mainly used for the capacity expansion of core pipeline products 5-hydroxymethylfurfural (HMF), 2,5-furandicarboxylic acid (FDCA) and 2,5-tetrahydrofuran dimethanol (THFDM), and the continuous development of downstream derivatives.Founded in 2021 with the vision of "Biomass Change Lives", GS Biotech is a bio-based material and R&D company dedicated to building a bio-based material industry chain. The members of its founding team graduated from the Dalian Institute of Chemical Physics, Chinese Academy of Sciences, and have nearly 20 years of research foundation and industrialization experience in the fields of biomass catalytic conversion and furan-based material design and development. At present, the R&D team building has also been completed from biomass, derivatives to polymers, which ensures the cutting-edge of the company's product development and the availability of end products.Acc...

Legend Capital Portfolio Company Atour Successfully Lists on Nasdaq

indie 13 11 月

3 minutes

HONG KONG, Nov 13, 2022 - (ACN Newswire via SEAPRWire.com) - On the evening of November 11, Beijing time, Legend Capital portfolio company Atour Lifestyle Holdings Limited ("Atour") was officially listed on the Nasdaq Stock Exchange in the United States. It has priced its initial public offering of 4,750,000 American Depositary Shares ("ADSs") at US$11.0 per ADS.Founded in 2013, Atour is a leading hospitality and lifestyle company in China with a distinct portfolio of lifestyle hotel brands, such as A.T. HOUSE, Atour S, ZHOTEL, Atour Hotel, Atour X and Atour Light, as well as scenario-based retail brands, including Atour Market. It has further divided its private labels into three product lines - aTOUR PLANET, SAVHE and Z2GO&CO. As of June 30, 2022, Atour has launched a total of 1,967 SKUs, 62.8% of which are private-label products. According to the prospectus, as of September 30, 2022, Atour has opened 880 hotels, a year-on-year increase of 26%. According to Frost & Sullivan, Atour is the largest upper midscale hotel chain with a diversified brand portfolio in China in terms of room numbers for five consecutive years as of the end of 2021. As an important institutional inv...

Legend Capital Portfolio Company Giant Biogene Successfully Lists on the HKEX

indie 7 11 月

4 minutes

HONG KONG, Nov 7, 2022 - (ACN Newswire via SEAPRWire.com) - On November 4, 2022, Legend Capital portfolio company Giant Biogene (2367.HK) was successfully listed on the main board of the Hong Kong Stock Exchange. The number of Giant Biogene's offer shares under the global offering is 22,608,800 shares at an issue price of HK$24.3 per share, which includes 2,261,200 Hong Kong offering shares, 20,347,600 international offering shares, as well as a 15% over-allotment option.Giant Biogene is a leader in the bioactive ingredient-based professional skin treatment product industry in China and the first company in the world to successfully develop and industrialize recombinant collagen skin treatment products. Giant Biogene has been the largest collagen-based professional skin treatment product company by retail sales in China for the latest three consecutive years since 2019. According to Frost & Sullivan, Giant Biogene was the second-largest professional skin treatment product company in China in 2021, and its Collgene and Comfy, the flagship brands of recombinant collagen-based products, were the third and the fourth best-selling professional skin treatment brands, respectively. Gi...

Led by Legend Capital, ClinBrain Completes Nearly CNY200 million Series C Round

indie 1 11 月

4 minutes

HONG KONG, Nov 1, 2022 - (ACN Newswire via SEAPRWire.com) - Recently, the healthcare big data leader ClinBrain completed the Series C round of financing of nearly CNY200 million, led by Legend Capital. This round of financing will facilitate ClinBrain to continuously deepen its expertise in the field of healthcare big data, explore the deep integration of big data and AI in the healthcare industry, promote the R&D of underlying technologies and scenario-based applications, and accelerate the promotion of industrial digital and intelligent upgrading.As a high-tech enterprise focusing on the healthcare big data intelligence platform, digitalized and intelligent application services, ClinBrain was shortlisted as the SDRI (specialized, refined, differential and innovative) "little giant" enterprise by the Ministry of Industry and Information Technology this year.At the beginning of its establishment in 2013, ClinBrain realized that healthcare, as a data-intensive and knowledge-intensive industry, is inseparable from the support of data, no matter in clinical services, operations management or medical research. ClinBrain has been committed to the direction of data governance and int...

Led by Legend Capital, Easy-Flow Raises Tens of Millions of CNY in Angel Round

indie 1 11 月

4 minutes

HONG KONG, Nov 1, 2022 - (ACN Newswire via SEAPRWire.com) - Shanghai Easy-Flow ("Easy-Flow") recently completed its Angel financing round by raising tens of millions of CNY, led by Legend Capital. The fresh capital will be used for the R&D of Easy-Flow's peripheral intervention pipeline.Data shows that there are a large number of patients with peripheral vascular disease, of which about 40 million patients with lower extremity arteries and about 100 million patients with varicose veins. Given the number of patients is increasing yearly, there is a huge clinical demand foreseeable, indicating that the peripheral vascular interventional device trajectory is likely to be the next market worth CNY10 billion.Founded in November 2021, Easy-Flow is committed to efficiently creating a complete set of solutions in the field of peripheral interventional devices. The company develops products such as drug balloons, catheters, stents, and thrombus removal equipment for treating peripheral arteriovenous diseases. Since its establishment, Easy-Flow has been committed to creating peripheral interventional product packages, and developing Me-too, Me-better and Me-only products at the same time...

Co-Led by Legend Capital, Top Gene Delivery Enterprise VectorBuilder Secures CNY410mn in Series C Round

indie 20 10 月

4 minutes

HONG KONG, Oct 20, 2022 - (ACN Newswire via SEAPRWire.com) - VectorBuilder Biotechnology (Guangzhou) Co., Ltd. (hereinafter referred to as "VectorBuilder"), a top gene delivery enterprise, recently announced the completion of its Series C round with CNY410 million, co-led by Legend Capital. The proceeds will facilitate VectorBuilder in continuously promoting the upgrading and capacity expansion of the gene delivery R&D and production technology platform, further accelerate the global business presence, and boost the R&D of life sciences and genetic medicines. VectorBuilder was founded by Dr. Bruce Lahn, a world-renowned molecular biologist who was a tenured professor at the University of Chicago and a researcher at Howard Hughes Medical Institute (HHMI). The company provides services such as scientific research and clinical carrier CRO, gene-drug CDMO and gene delivery IP out-licensing, covering the entire field of life science and gene medicine. VectorBuilder has provided more than 1.2 million gene delivery solutions to more than 4,000 scientific research institutes and pharmaceutical companies worldwide, and its gene-drug CRO and CDMO projects are spread all over North Am...

GalaxySpace Completes a New Financing Round with Legend Capital Re-upped

indie 25 9 月

3 minutes

HONG KONG, Sep 25, 2022 - (ACN Newswire via SEAPRWire.com) - GalaxySpace, a Chinese commercial aerospace company, recently completed its latest financing round with a post-investment valuation of approximately RMB11 billion. As an existing shareholder, Legend Capital continued to support the company by following up on this financing round.Legend Capital first invested in GalaxySpace in 2018 and continued to follow up on the company's subsequent financing rounds in 2019, 2020 and 2022, increasing its investment layout of cutting-edge technology and supporting the development of GalaxySpace.Founded in 2018, GalaxySpace is the first unicorn enterprise in the field of commercial aerospace and satellite internet in China. Xu Ming, founder, chairman and CEO of GalaxySpace, said: "This round of financing will be mainly used for the R&D of satellite Internet-related technologies and the development of commercial applications. GalaxySpace will accelerate the R&D of core technologies such as stackable flat panel satellites, flexible multi-beam phased array technology, flexible solar wings, digital processing payloads, etc., and also the construction of mass-producing low-cost satelli...

Leadrive Technology Completes Series C Financing, Legend Capital Re-upped

indie 25 9 月

3 minutes

HONG KONG, Sep 25, 2022 - (ACN Newswire via SEAPRWire.com) - Leadrive Technology, a leading supplier of power semiconductor and motor control solutions for new energy vehicles, recently announced its completion of the series C financing. As the existing shareholder, Legend Capital continued to support this round of financing.This round of financing will be mainly used for the construction of the IGBT/SiC power module packaging production line, the operation of the rapid production of motor control products, and the R&D of the latest generation of silicon carbide power modules and motor control products.Founded in 2017, Leadrive Technology has been committed to the forward development and production of power semiconductor modules and high-performance motor control units, bringing high-quality electric power to global automotive enterprise customers and consumers. After five years of rapid development, Leadrive Technology is equipped with mature technology and product solutions in the power modules and motor control units. A variety of high-performance IGBT power modules and main-drive dual-motor controller products developed by Leadrive have been installed in several hybrid mode...

Legend Capital: The Logic of Technology Investment Has Changed

indie 2 9 月

10 minutes

HONG KONG, Sep 2, 2022 - (ACN Newswire via SEAPRWire.com) - Legend Capital recently announced that it made its 100th IPO following the listing of its AI medical portfolio company Lunit on the KOSDAQ market on 21 July 2022. In addition, Legend Capital's CRO portfolio company R&G Pharmastudies was successfully listed on the ChiNext of Shenzhen Stock Exchange on 2 August 2022, while on 5 August 2022, the innovative drug portfolio company MicuRx Pharmaceuticals went public on the STAR Market, becoming the 101st IPO and the 102nd IPO in Legend Capital's investment portfolio. In a recent interview, Richard Li, President of Legend Capital, revealed the history of Legend Capital in technology investment and proposed that the logic of technology investment has undergone important changes.Over 100 IPOs and 100 UnicornsLegend Capital pays more attention to the quality rather than the quantity of IPOs, but the 100th IPO remarks an important milestone for Legend Capital. Richard Li, President of Legend Capital, said in the interview: "What matters is not about the quantity of IPOs, but more about the repeated verification of the investment expertise of Legend Capital team, who has long been...

Pursued progress while ensuring stability and built up momentum, Legend Holdings realized revenue of RMB237,685 million in the first half of 2022

indie 31 8 月

8 minutes

HONG KONG, Aug 31, 2022 - (ACN Newswire via SEAPRWire.com) - Legend Holdings Corporation (stock code: 3396.HK) announced today the unaudited condensed consolidated interim results for the six months ended June 30, 2022 (the "Reporting Period"). During the Reporting Period, the Company's revenue was RMB237,685 million and the net profit attributable to equity holders of the Company amounted to RMB2,131 million.Mr. Li Peng, Executive Director and CEO of Legend Holdings, said that in the face of the complex international environment, in the first half of 2022, Legend Holdings pursued progress while ensuring stability, and deepened the strategic thinking of "industrial operation, technological innovation", made steady improvement in its corporate competitiveness and operational efficiency, and further strengthened its investment and layout in the field of science and technology innovation; At the same time, we gave full play to the role of "chain leader", practiced the concept of green development, actively fulfilled corporate social responsibility, and devoted ourselves to contribute to the high-quality development of China's economy.During the Reporting Period, Legend Holdings furthe...

Led by Legend Capital, Multi-omics-leading Enterprise APTBIO Closes Series B with Hundreds of Millions of CNY

indie 19 8 月

4 minutes

HONG KONG, Aug 19, 2022 - (ACN Newswire via SEAPRWire.com) - Shanghai Applied Protein Technology Co., Ltd. ("APTBIO"), a leading enterprise focused on mass spectrometry-based multi-omics applied to precision medicine, recently announced the completion of its Series B with hundreds of millions of CNY, which is led by Legend Capital. The proceeds from this round of financing will be used to accelerate the product R&D, market expansion, and data-driven precision medicine development and help APTBIO continue to develop in mass spectrometry multi-omics applications, innovative drug development, and preclinical research, making a forward-looking layout for the construction of precision medicine services driven by big data and AI. Founded in July 2004, APTBIO is one of the earliest biotechnology companies engaged in proteomics technical services and biopharmaceutical research and analysis services in China and participated in establishing China's biological mass spectrometry applications from scratch. With headquarter in Shanghai, APTBIO has a nationwide sales network and it has built innovative technology centers, data centers, and clinical testing centers in Shanghai, Yiwu, and Taiz...

Legend Capital Portfolio: China-leading CRO Enterprise R&G Pharmastudies Listed on the ChiNext Market Successfully

indie 15 8 月

3 minutes

HONG KONG, Aug 15, 2022 - (ACN Newswire via SEAPRWire.com) - On August 2, 2022, R&G Pharmastudies Co., Ltd. (stock code: 301333.SZ), a China-leading CRO enterprise invested by Legend Capital, was successfully listed on the ChiNext of Shenzhen Stock Exchange. R&G Pharmastudies publicly issued 15,000,000 shares at a price of RMB78.88 per share, and the total amount of funds raised is expected to be RMB1.18 billion.R&G PharmaStudies is a large-scale professional clinical trial outsourcing service supplier in China. It has established a complete set of pharmaceutical R&D outsourcing service systems covering the whole chain of clinical trials. R&G PharmaStudies provides integrated services throughout the entire process of clinical trials with its comprehensive drug R&D service system; the main services offered by the company cover clinical trial operation services, clinical trial site management services, biological sample testing services, data management, and statistical analysis services, clinical trial consulting services, clinical pharmacology services, etc. R&G PharmaStudies is committed to providing high-quality and efficient clinical research services...

Legend Capital Super Antibiotic Portfolio Company: Scarce Enterprise MicuRx Pharmaceuticals is Listed on the STAR Market Successfully

indie 9 8 月

4 minutes

HONG KONG, Aug 9, 2022 - (ACN Newswire via SEAPRWire.com) - On August 5, 2022, Legend Capital portfolio company MicuRx Pharmaceuticals, a scarce enterprise in super antibiotic, was successfully listed on the STAR Market. MicuRx Pharmaceuticals issued 130,000,000 shares this time, accounting for 19.84% of the total share capital after the issuance. The total amount of funds raised is expected to be about RMB 960 million at the issue price of 8.16 yuan per share. MicuRx Pharmaceuticals is an innovative drug company focusing on novel therapeutics for infectious diseases. With global independent intellectual property and competitiveness, MicuRx Pharmaceuticals is committed to the discovery, development, and commercialization of innovative drugs for unmet medical needs. The main products from MicuRx Pharmaceuticals include Contezolid, MRX-4, and MRX-8. Since the company's establishment, MicuRx Pharmaceuticals has adhered to the principle of "Better therapy through superior medicine", focusing on the increasingly severe problem of bacterial resistance worldwide. With the core competitiveness of solving clinical problems and differentiated innovation, MicuRx Pharmaceuticals aims to provid...

New Power to Legend Capital Carbon Neutral Investment Portfolio: Ruicycle Raises Over RMB 300 Million from Series B

indie 8 8 月

4 minutes

HONG KONG, Aug 8, 2022 - (ACN Newswire via SEAPRWire.com) - Shenzhen Ruicycle Environmental Protection Technology Co., Ltd (also known as Hengchuang Ruineng), a battery recycling company, recently accomplished the B round of fundraising with over RMB 300 million, which is backed by Legend Capital. This round of fundraising will be mainly used to improve the development of the echelon utilized product series, the construction of new energy retired lithium battery recycling capacity, and the expansion of new lithium battery wet recycling technology.Founded in 2017, Ruicycle is a national high-tech enterprise dedicated to "Making New Energy a Truly Green Energy", deeply engaging in the field of recycling and comprehensive utilization of retired power batteries. It is committed to pursuing the concept of green and low-carbon development. Directing at the end of the new energy industry, Ruicycle has built an industrial ecological closed loop of large-scale automatic safe crushing, zero-pollution treatment, and high-efficiency recycling of lithium batteries based on the core technologies of lithium battery echelon utilization, material regeneration, and new material regeneration. Meanwhi...

Led by Legend Capital, The Leading Intelligent Special Robot Company AKA Robotics Completes Series A Financing

indie 28 7 月

3 minutes

HONG KONG, Jul 28, 2022 - (ACN Newswire via SEAPRWire.com) - Shenzhen AKA Robotics Technology Co., LTD. (hereinafter referred to as "AKA Robotics"), a leading intelligent special robot company, recently completed its Series A financing round, which was led by Legend Capital. This round of funds will be used to invest in R&D and accelerate its market expansion of the special robotic series products and its overseas market layout, with the mission of "cleaning the world, safe operation".AKA Robotics was established in 2017 and has grown into an enterprise that provides intelligent special robots and comprehensive green solutions for rust removal, cleaning, spraying, polishing, and the inspection of large steel-structure facades. Its robot products have been widely used in ships, petrochemicals, wind power, and other industries.The founding team of AKA Robotics was formed by experts in the field of robotics, coming from Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences. The founder of AKA Robotics is a key technical talent of the Chinese Academy of Sciences, the chief scientist of key R&D projects of the Ministry of Science and Technology, a doctoral super...

GameFi on Fire: Dragon Crypto Gaming’s Dragon Crypto Argenti Token ($DCAR) and The Legend of Aurum Draconis

pandora 22 7 月

4 minutes

Sydney, Australia, July 22, 2022 – (SEAPRWire) – Dragon Crypto Gaming (DCG) initial dex offering (IDO) of Dragon Crypto Argenti ($DCAR), a utility token for its expanding GameFi ecosystem, will be open for registration on July 20th, 2022, with the IDO taking place on July 26th, 2022. DCG has partnered with Avalaunch, the leading platform for decentralized fundraising on Avalanche. Following the token release, The Legend of Aurum Draconis, an action-adventure role playing game (RPG), will go live on the Avalanche C-chain blockchain soon after. Founded by a team of experienced and passionate software developers and gamers, Dragon Crypto Gaming is building an evolving digital universe that combines engaging gameplay with play-and-earn mechanics, user ownership and sustainable economics. DCG’s game offerings are established on a dual token economy featuring two native tokens: Dragon Crypto Aurum ($DCAU) and $DCAR. Both tokens have major utility in all DCG game offerings. From the outset, $DCAR will drive the economics of crafting and land-ownership in The Legend of Aurum Draconis. Players can also stake $DCAR to earn a share of platform revenues. Future utility includes being the nativ...

Legend Capital Portfolio Company: The Global-Leading AI Medical Imaging Company Lunit Goes Public Successfully

indie 21 7 月

5 minutes

HONG KONG, Jul 21, 2022 - (ACN Newswire via SEAPRWire.com) - On July 21st, 2022, Lunit, a leading global AI-based cancer solutions provider invested by Legend Capital, was successfully listed on the KOSDAQ market. Founded in 2013, Lunit successfully established itself as the world's top-notch artificial intelligence technology solution provider, mainly focusing on developing medical software to assist physicians in the realm of tumor diagnosis and treatment. Lunit's flagship products are Lunit INSIGHT and Lunit SCOPE. Lunit INSIGHT is an AI-powered image screening solution, that detects and classifies chest abnormalities and breast cancer. Lunit SCOPE is an AI biomarker for immunotherapy, providing therapy response information that can critically affect treatment outcomes for cancer patients. Legend Capital led Lunit's series B investment round in June 2018 and continued to support Lunit's global business expansion via three additional follow-on investments in 2019 and 2021. For the past 4 years, Lunit not only has produced world-leading AI medical solutions but also gained its commercial value achieving rapid topline growth. Lunit's annual revenue grew by over 460% in 2021 since i...

Co-led by Legend Capital, Huili Biotechnology Completes Series A Financing Round with Hundreds of Million RMB

indie 7 7 月

4 minutes

HONG KONG, Jul 7, 2022 - (ACN Newswire via SEAPRWire.com) - Jiangsu Huili Biotechnology Co., Ltd ("Huili Bio"), a next-generation synthetic biology enzyme computational design platform, recently announced the completion of its Series A financing round with hundreds of million RMB. This financing round was co-led by Legend Capital and the fresh capital will be used to accelerate the construction and operation of large-scale production facilities, the R&D of new product pipelines and the expansion of the talent team.Founded in 2018, Huili Bio is dedicated to the computational design of enzyme components at the core of synthetic biological reactions. With cutting-edge achievements, Huili Bio is one of the few bio-manufacturing companies with comprehensive capabilities in core technology, mass production on a large scale and closed-loop commercialization. It provides solutions in multiple fields such as pharmaceutical intermediates, animal protection and food. In addition to an R&D center in Tianjin, Huili Bio has also established a production base in Taizhou City, Jiangsu Province, which is under the expansion of flexible production line. Huili Bio's enzyme computational desig...

Copyright © 2020 ASEANPR.Com All rights reserved.